Víctor Alfonso Jiménez Díaz: SAPT or DAPT in Valve-in-Valve TAVI? Walking a Fine Line
Víctor Alfonso Jiménez Díaz, Director, Cardiovascular Research Unit, Hospital Álvaro Cunqueiro at Hospital Álvaro Cunqueiro, University Hospital Complex of Vigo, shared a post on LinkedIn:
“SAPT or DAPT in Valve-in-Valve TAVI? Walking a Fine Line

Antithrombotic therapy after TAVI remains one of the most complex challenges in structural heart interventions. Although the POPular TAVI trial shifted the balance toward single antiplatelet therapy (SAPT) in the general population, can we apply the same logic to Valve-in-Valve (ViV) procedures?
We have just published our editorial comment in JACC: Cardiovascular Interventions: “Still Walking a Fine Line,” where we analyze the interesting study by Bendandi et al. on the use of SAPT vs. DAPT in ViV procedures.
Why is the ViV scenario different?
-In ViV, altered anatomy and hemodynamic limitations can amplify thrombotic risk.
-Evidence from native TAVI is not always extrapolable to patients with failed bioprostheses.
-The balance between bleeding risk and leaflet thrombosis is, now more than ever, a “fine line.”
This editorial highlights the urgent need for subgroup-specific data and individualized decision-making.
Congratulations to my colleague Cláudio Espada Guerreiro for this analysis and to Francesco Bendandi, Palmerini Tullio, Federico De Marco, Cosmo Godino, Chiara Fraccaro, Marco Barbanti, francesco maisano, Francesco Saia and the entire Italian team for the original research.
Read the full editorial here”
Title: Dual vs Single Antiplatelet Therapy After Valve-in-Valve TAVR: Still Walking a Fine Line
Authors: Victor Alfonso Jimenez Diaz, Claudio Guerreiro

Get the latest updates with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series